A5058417767- Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- Viral-associated cancers and disorders
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- AI in cancer detection
- Vascular Tumors and Angiosarcomas
- Histiocytic Disorders and Treatments
- Fungal Infections and Studies
- Sarcoma Diagnosis and Treatment
- Hematological disorders and diagnostics
- Malaria Research and Control
- Acute Lymphoblastic Leukemia research
- Cell Image Analysis Techniques
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Cancer and Skin Lesions
- Phagocytosis and Immune Regulation
- Immunodeficiency and Autoimmune Disorders
- Parvovirus B19 Infection Studies
Stanford University
2016-2025
Palo Alto University
2021-2024
Stanford Medicine
2020-2023
University of Oslo
2020
King's College Hospital NHS Foundation Trust
2020
Amgen (Germany)
2020
Massachusetts General Hospital
2020
Harvard University
2020
Stanford Cancer Institute
2017-2019
Cancer Institute (WIA)
2017-2019
Abstract Adoptively transferred T cells and agents designed to block the CD47–SIRPα axis are promising cancer therapeutics that activate distinct arms of immune system 1,2 . Here we administered anti-CD47 antibodies in combination with adoptively goal enhancing antitumour efficacy but observed abrogated therapeutic benefit due rapid macrophage-mediated clearance expressing chimeric antigen receptors (CARs) or engineered cell receptors. Anti-CD47-antibody-mediated CAR was potent enough serve...
Abstract Most cellular ubiquitin signaling is initiated by UBA1, which activates and transfers to tens of E2 enzymes. Clonally acquired UBA1 missense mutations cause an inflammatory-hematologic overlap disease called VEXAS (vacuoles, E1, X-linked, autoinflammatory, somatic) syndrome. Despite extensive clinical investigation into this lethal disease, little known about the underlying molecular mechanisms. Here, dissecting VEXAS-causing mutations, we discovered that p.Met41 alter cytoplasmic...
Murine double minute 2 (MDM2) inhibitors have shown promising activity in TP53-wild type tumors and are under active investigation across a spectrum of malignancies. Herein, we report 51-year-old female with MDM2-amplified, adenoid cystic carcinoma who was treated MDM2 inhibitor developed persistent pancytopenia despite drug discontinuation. Her associated 20 distinct pathogenic TP53 mutations peripheral blood bone marrow not present drug-resistant tumor tissue. Plasma were similarly...
Abstract Objectives Recent studies show that blocking CD47-SIRPα interactions is a promising target in checkpoint inhibition for cancer immunotherapy. However, to date, the expression of CD47 not well characterized various hematolymphoid neoplasms. Methods This study evaluates wide range neoplasms using immunohistochemistry on 834 cases. Results variable but widespread among tumor types and within individual samples both intensity percentage. The highest expressions percentage positive...
Key Points PD-L1 structural variants are recurrent in mycosis fungoides with large cell transformation. relapsed/refractory should prompt consideration of treatment PD-1 inhibitors.
Abstract Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Though histologically DLBCL shows varying morphologies, no morphologic features have been consistently demonstrated to correlate with prognosis. We present a analysis of histology sections from 209 cases associated clinical and cytogenetic data. Duplicate tissue core were arranged in microarrays (TMAs), replicate stained H&E immunohistochemical stains for CD10, BCL6, MUM1, BCL2, MYC. The TMAs are...
We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) negative infectious workup beginning median 92.5 days (range: 22-210 days) after CAR-T 85 cytokine release syndrome resolution. Gut biopsies uniformly...
Eukaryotic parasites of the genus Plasmodium cause malaria by invading and developing within host erythrocytes. Here, we demonstrate that PfShelph2, a gene product falciparum belongs to Shewanella-like phosphatase (Shelph) subfamily, selectively hydrolyzes phosphotyrosine, as shown for other previously studied Shelph family members. In extracellular merozoite stage, PfShelph2 localizes vesicles appear be distinct from those rhoptry, dense granule, or microneme organelles. During invasion, is...
Here, we utilize a high throughput sequencing panel that covers several genes known to be recurrently mutated in certain T-cell lymphoma subtypes as well frequently other hematolymphoid malignancies, including myeloid neoplasms. This was applied formalin-fixed, paraffin-embedded tissue from 84 biopsies 78 patients selected for this study. The included ones with diagnosis of (n=79), peripheral not otherwise specified (PTCL-NOS; n=26) and angioimmunoblastic (AITL; n=13), 5 cases atypical...
Abstract Hypereosinophilia (HE) has been defined as persistent eosinophilia >1.5 × 109/L; it is broadly divided into primary HE (clonal or neoplastic; HEN), secondary/reactive (HER), of undetermined significance (HEUS) when no cause identified. The use myeloid next-generation sequencing (NGS) panels led to the detection several mutations in patients previously diagnosed with HEUS, reassigning some category HEN, specifically World Health Organization chronic eosinophilic leukemia, not...